Inovio Archives | Be Korea-savvy
Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019

Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019

PLYMOUTH MEETING, Pa., Nov. 26 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that three recent published studies of its DNA-Encoded monoclonal antibody (dMAb™) technology showed impressive results in treating cardiovascular disease and in preventing infection from the Ebola virus and Lyme disease-causing bacteria in preclinical models. Leveraging several recent published positive preclinical [...]

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

PLYMOUTH MEETING, Pa., Oct. 25 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. In this reported study, PENNVAX-GP plasmids were delivered intradermally or intramuscularly [...]

Inovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018

Inovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018

PLYMOUTH MEETING, Pa., Oct. 24 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its 2018 third quarter financial results on Thursday, November 8, 2018 at 4:30 p.m. ET. A live and archived version of the audio presentation will be available online [...]

Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

PLYMOUTH MEETING, Pa., Oct. 22 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data from the company’s recently completed Phase 1b study with INO-5150 demonstrated a slowing of Prostate-Specific Antigen Doubling Time (PSADT) in men with prostate cancer. Eighty six percent (86%) of patients remained progression-free at Week 72 of the study. [...]

Inovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants

Inovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants

PLYMOUTH MEETING, Pa., Oct. 17 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received the first two U.S. patents for its DNA-encoded monoclonal antibody technology (dMAb™) from the U.S. Patent & Trademark Office and has been awarded a $2.2 million grant from the Bill & Melinda Gates Foundation to advance its [...]

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

PLYMOUTH MEETING, Pa., Sept. 17 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a [...]